To evaluate the efficacy of imiquimod 5% in periungual wart treatment.
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), moderate (25 mm 2 <total lesion area ≤ 50 mm 2 ), severe (total lesion area > 50 mm 2 ). The outcome was evaluated at the 4 th and the 8 th week. The result was graded as excellent (complete clearance), good (≥ 50% clearance) and poor (< 50% clearance).
RESULTS:
The total area of the wart lesion got decreased significantly from the beginning to the 4 th 
Introduction
Periungual warts a common skin disease and can interfere with nails development, mainly in immunosuppressed patients [1] , [2] .
Tissue destruction therapy is painful, and the recurrence is frequent. Imiquimod is a topical immunosuppressive agent, which stimulates the production of inflammatory cytokines that activate and maintain cell-mediated immune response [3] .
This study aimed to evaluate the efficacy of imiquimod 5%, once daily for 5 consecutive days per week, in periungual wart treatment in 40 Vietnamese patients, including 19 females (aged 20.4 ± 13.8) and 21 males (aged 27.3 ± 13.5) patients.
Material and Methods
A group of 40 patients were recruited to apply imiquimod 5 % cream once daily for 5 consecutive days per week in 8 weeks. They were classified into 3 levels: Mild (the total lesion area ≤ 25 mm The outcome was evaluated at the 4th and the 8th week.
The result was graded as excellent (complete clearance), good (≥ 50% clearance) and poor (< 50% clearance).
Results
The warts condition before the treatment was mild in 21 patients (52.5%) (the total lesion area ≤ 25 mm 2 ), moderate in 8 patients (20.0%) (25 mm 2 <total lesion area ≤ 50 mm 2 ) and severe in 11 patients (27.5%) (total lesion area > 50 mm 2 ). The duration of disease was 13.5 ± 15.0 months. The total area of warts got decreased significantly from 36.7mm 2 at week 0 to 16.8 mm 2 at the 4 th week and 8.8 mm 2 at the 8 th week (p < 0.05) as shown in Figure 1 . The excellent outcome at the 8 th week was higher than that at the week 4 th significantly (72.5% vs 22.5%, p = 0.04). The complete clearing rate at the 8 th week was significantly higher than that at the 4 th week due to the slow effect of imiquimod in stimulating immune cells.
Figure 2: Periungual warts before (A) and after (B) treatment with imiquimod 5 % cream
An excellent outcome was seen in 68.2% of people who had got treated by other modalities before applying imiquimod and 77.8% of naïve patients, the difference was not significant (p = 0.37, Fisher exact test) ( Table 1) . No systemic side effects have been reported. Local side effects had been seen in 37.5% patients, but 73.33% of the side effect was mild.
After 6 months of follow-up, there was only one relapse case (3.5%) after 3 months.
Discussion
Excellent results in a group of patients suffering mild/moderate wart were higher than that of the group having severe wart (82.8% vs 45.5%, p = 0.03). So longer the duration of disease was, the less effective the treatment modality was [4] , [5] , [6] .
There was only one relapse case after 3 months. It could be explained by the ability of imiquimod cream that can start and maintain HPV specific cell-mediated immunity [7] , [8], [9] , [10] .
In conclusions, Imiquimod 5% cream is safe and effective drug in the treatment of periungual warts. Early treatment leads to better results.
